分子诊断公司Co-Diagnostics Inc.宣布，已正式提交一份公司章程修正案，计划对其已发行的普通股进行反向股票分割，分割比例为1比30。这意味着，每30股现有普通股将合并为1股新股。此项举措旨在调整公司股本结构，通常被上市公司用于提升每股股价，以满足交易所的持续上市标准或改善投资者的观感。该修正案生效后，公司普通股的总股数将相应减少，而每股面值不变。
分子诊断公司Co-Diagnostics Inc.宣布，已正式提交一份公司章程修正案，计划对其已发行的普通股进行反向股票分割，分割比例为1比30。这意味着，每30股现有普通股将合并为1股新股。此项举措旨在调整公司股本结构，通常被上市公司用于提升每股股价，以满足交易所的持续上市标准或改善投资者的观感。该修正案生效后，公司普通股的总股数将相应减少，而每股面值不变。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.